William Blair initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Wednesday morning, MarketBeat reports. The firm issued an outperform rating on the biotechnology company’s stock.

Several other research firms also recently issued reports on CLLS. ValuEngine downgraded shares of Cellectis from a buy rating to a hold rating in a report on Friday, November 16th. Zacks Investment Research upgraded shares of Cellectis from a hold rating to a buy rating and set a $25.00 price objective on the stock in a report on Friday, November 16th. Oppenheimer set a $44.00 price objective on shares of Cellectis and gave the stock a buy rating in a report on Sunday, November 25th. BidaskClub downgraded shares of Cellectis from a sell rating to a strong sell rating in a report on Wednesday, November 21st. Finally, Barclays restated a buy rating and set a $50.00 price objective on shares of Cellectis in a report on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $32.00.

NASDAQ:CLLS opened at $19.31 on Wednesday. Cellectis has a 52-week low of $15.34 and a 52-week high of $38.85. The stock has a market cap of $792.48 million, a PE ratio of -10.01 and a beta of 1.76.

A number of hedge funds and other institutional investors have recently bought and sold shares of CLLS. Macquarie Group Ltd. bought a new stake in Cellectis in the third quarter valued at about $5,390,000. Opaleye Management Inc. bought a new stake in Cellectis in the third quarter valued at about $3,104,000. New York State Common Retirement Fund bought a new stake in Cellectis in the fourth quarter valued at about $1,658,000. Morgan Stanley increased its stake in Cellectis by 25.2% in the third quarter. Morgan Stanley now owns 481,450 shares of the biotechnology company’s stock valued at $13,586,000 after acquiring an additional 96,847 shares during the period. Finally, Sphera Funds Management LTD. increased its stake in Cellectis by 27.3% in the third quarter. Sphera Funds Management LTD. now owns 447,970 shares of the biotechnology company’s stock valued at $12,642,000 after acquiring an additional 96,096 shares during the period. 27.62% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Recommended Story: What causes a recession?

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.